Epalrestat is the second aldose reductase inhibitor to be introduced worldwide and the
first to be launched in Japan. The compound is indicated for the treatment of diabetic
neuropathy. It is also being investigated for diabetic retinopathy and nephropathy.
화학적 성질
Red Solid
용도
Epalrestat is an aldose reductase inhibitor with IC50 of 72 nM
정의
ChEBI: A monocarboxylic acid that is 1,3-thiazolidine which is substituted on the nitrogen by a carboxymethyl group, at positions 2 and 4 by thioxo and oxo groups, respectively, and at position 5 by a 2-methyl-3-phenylprop-2-en-1-ylidene group. It is an inhibitor
of aldose reductase (which catalyses the conversion of glucose to sorbitol) and is used for the treatment of some diabetic complications, including neuropathy.